Jun 29, 2021 Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Apr 29, 2021 Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
Apr 15, 2021 Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
Nov 24, 2020 Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
Oct 12, 2020 Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020
Sep 30, 2020 Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
